Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Antiviral Res ; 117: 115-21, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25746331

RESUMO

Brincidofovir (BCV) has broad-spectrum in vitro activity against dsDNA viruses, including smallpox, and is being developed as a treatment for smallpox as well as infections caused by other dsDNA viruses. BCV has previously been shown to be active in multiple animal models of smallpox. Here we present the results of a randomized, blinded, placebo-controlled study of the efficacy and pharmacokinetics of a novel, "humanized" regimen of BCV for treatment of New Zealand White rabbits infected with a highly lethal inoculum of rabbitpox virus, a well characterized model of smallpox. Compared with placebo, a dose-dependent increase in survival was observed in all BCV-treatment groups. Concentrations of cidofovir diphosphate (CDV-PP), the active antiviral, in rabbit peripheral blood mononuclear cells (PBMCs) were determined for comparison to those produced in humans at the dose proposed for treatment of smallpox. CDV-PP exposure in PBMCs from rabbits given BCV scaled to human exposures at the dose proposed for treatment of smallpox, which is also currently under evaluation for other indications. The results of this study demonstrate the activity of BCV in the rabbitpox model of smallpox and the feasibility of scaling doses efficacious in the model to a proposed human dose and regimen for treatment of smallpox.


Assuntos
Citosina/análogos & derivados , Modelos Animais de Doenças , Organofosfonatos/farmacocinética , Organofosfonatos/uso terapêutico , Coelhos , Varíola/tratamento farmacológico , Vaccinia virus/efeitos dos fármacos , Vacínia/tratamento farmacológico , Animais , Anticorpos Neutralizantes/sangue , Anticorpos Antivirais/sangue , Antivirais/farmacocinética , Antivirais/uso terapêutico , Cidofovir , Citosina/administração & dosagem , Citosina/farmacocinética , Citosina/farmacologia , Citosina/uso terapêutico , Humanos , Injeções Intradérmicas , Organofosfonatos/administração & dosagem , Organofosfonatos/farmacologia , Distribuição Aleatória , Vacínia/virologia , Vaccinia virus/crescimento & desenvolvimento , Vírus da Varíola/efeitos dos fármacos , Vírus da Varíola/crescimento & desenvolvimento
2.
J Virol ; 89(6): 3295-307, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25589648

RESUMO

UNLABELLED: Protection from lethality by postchallenge administration of brincidofovir (BCV, CMX001) was studied in normal and immune-deficient (nude, nu/nu) BALB/c mice infected with vaccinia virus (VACV). Whole-body bioluminescence imaging was used to record total fluxes in the nasal cavity, lungs, spleen, and liver and to enumerate pox lesions on tails of mice infected via the intranasal route with 10(5) PFU of recombinant IHD-J-Luc VACV expressing luciferase. Areas under the flux curve (AUCs) were calculated for individual mice to assess viral loads. A three-dose regimen of 20 mg/kg BCV administered every 48 h starting either on day 1 or day 2 postchallenge protected 100% of mice. Initiating BCV treatment earlier was more efficient in reducing viral loads and in providing protection from pox lesion development. All BCV-treated mice that survived challenge were also protected from rechallenge with IHD-J-Luc or WRvFire VACV without additional treatment. In immune-deficient mice, BCV protected animals from lethality and reduced viral loads while animals were on the drug. Viral recrudescence occurred within 4 to 9 days, and mice succumbed ∼10 to 20 days after treatment termination. Nude mice reconstituted with 10(5) T cells prior to challenge with 10(4) PFU of IHD-J-Luc and treated with BCV postchallenge survived the infection, cleared the virus from all organs, and survived rechallenge with 10(5) PFU of IHD-J-Luc VACV without additional BCV treatment. Together, these data suggest that BCV protects immunocompetent and partially T cell-reconstituted immune-deficient mice from lethality, reduces viral dissemination in organs, prevents pox lesion development, and permits generation of VACV-specific memory. IMPORTANCE: Mass vaccination is the primary element of the public health response to a smallpox outbreak. In addition to vaccination, however, antiviral drugs are required for individuals with uncertain exposure status to smallpox or for whom vaccination is contraindicated. Whole-body bioluminescence imaging was used to study the effect of brincidofovir (BCV) in normal and immune-deficient (nu/nu) mice infected with vaccinia virus, a model of smallpox. Postchallenge administration of 20 mg/kg BCV rescued normal and immune-deficient mice partially reconstituted with T cells from lethality and significantly reduced viral loads in organs. All BCV-treated mice that survived infection were protected from rechallenge without additional treatment. In immune-deficient mice, BCV extended survival. The data show that BCV controls viral replication at the site of challenge and reduces viral dissemination to internal organs, thus providing a shield for the developing adaptive immunity that clears the host of virus and builds virus-specific immunological memory.


Assuntos
Antivirais/administração & dosagem , Citosina/análogos & derivados , Organofosfonatos/administração & dosagem , Substâncias Protetoras/administração & dosagem , Linfócitos T/citologia , Vaccinia virus/efeitos dos fármacos , Vacínia/tratamento farmacológico , Animais , Citosina/administração & dosagem , Feminino , Humanos , Luciferases/genética , Luciferases/metabolismo , Contagem de Linfócitos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Linfócitos T/imunologia , Vacínia/imunologia , Vacínia/mortalidade , Vacínia/virologia , Vaccinia virus/genética , Vaccinia virus/fisiologia , Carga Viral/efeitos dos fármacos
3.
Antiviral Res ; 111: 42-52, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25128688

RESUMO

Natural orthopoxvirus outbreaks such as vaccinia, cowpox, cattlepox and buffalopox continue to cause morbidity in the human population. Monkeypox virus remains a significant agent of morbidity and mortality in Africa. Furthermore, monkeypox virus's broad host-range and expanding environs make it of particular concern as an emerging human pathogen. Monkeypox virus and variola virus (the etiological agent of smallpox) are both potential agents of bioterrorism. The first line response to orthopoxvirus disease is through vaccination with first-generation and second-generation vaccines, such as Dryvax and ACAM2000. Although these vaccines provide excellent protection, their widespread use is impeded by the high level of adverse events associated with vaccination using live, attenuated virus. It is possible that vaccines could be used in combination with antiviral drugs to reduce the incidence and severity of vaccine-associated adverse events, or as a preventive in individuals with uncertain exposure status or contraindication to vaccination. We have used the intranasal mousepox (ectromelia) model to evaluate the efficacy of vaccination with Dryvax or ACAM2000 in conjunction with treatment using the broad spectrum antiviral, brincidofovir (BCV, CMX001). We found that co-treatment with BCV reduced the severity of vaccination-associated lesion development. Although the immune response to vaccination was quantifiably attenuated, vaccination combined with BCV treatment did not alter the development of full protective immunity, even when administered two days following ectromelia challenge. Studies with a non-replicating vaccine, ACAM3000 (MVA), confirmed that BCV's mechanism of attenuating the immune response following vaccination with live virus was, as expected, by limiting viral replication and not through inhibition of the immune system. These studies suggest that, in the setting of post-exposure prophylaxis, co-administration of BCV with vaccination should be considered a first response to a smallpox emergency in subjects of uncertain exposure status or as a means of reduction of the incidence and severity of vaccine-associated adverse events.


Assuntos
Antivirais/administração & dosagem , Citosina/análogos & derivados , Vírus da Ectromelia/fisiologia , Ectromelia Infecciosa/prevenção & controle , Organofosfonatos/administração & dosagem , Vacina Antivariólica/administração & dosagem , Animais , Citosina/administração & dosagem , Vírus da Ectromelia/imunologia , Ectromelia Infecciosa/imunologia , Ectromelia Infecciosa/virologia , Feminino , Humanos , Imunidade , Camundongos , Camundongos Endogâmicos C57BL , Vacina Antivariólica/imunologia , Vacinação , Replicação Viral
4.
Antimicrob Agents Chemother ; 58(9): 5570-1, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24957837

RESUMO

Brincidofovir (CMX001), a lipid conjugate of the acyclic nucleotide phosphonate cidofovir, is under development for smallpox treatment using "the Animal Rule," established by the FDA in 2002. Brincidofovir reduces mortality caused by orthopoxvirus infection in animal models. Compared to cidofovir, brincidofovir has increased potency, is administered orally, and shows no evidence of nephrotoxicity. Here we report that the brincidofovir half-maximal effective concentration (EC50) against five variola virus strains in vitro averaged 0.11 µM and that brincidofovir was therefore nearly 100-fold more potent than cidofovir.


Assuntos
Antivirais/farmacologia , Citosina/análogos & derivados , Organofosfonatos/farmacologia , Varíola/tratamento farmacológico , Vírus da Varíola/efeitos dos fármacos , Animais , Linhagem Celular , Chlorocebus aethiops , Cidofovir , Citosina/farmacologia , DNA Viral/análise , DNA Viral/genética , Modelos Animais de Doenças , Humanos , Técnicas In Vitro , Testes de Sensibilidade Microbiana , Vírus da Varíola/crescimento & desenvolvimento
5.
Antimicrob Agents Chemother ; 56(5): 2726-34, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22391537

RESUMO

CMX001 is a novel, broad-spectrum lipid antiviral conjugate (LAC) that produces high intracellular levels of the active antiviral agent cidofovir diphosphate (CDV-PP). Study CMX001-102 was a randomized, double-blind, placebo-controlled, parallel group, dose-escalating study in healthy volunteers. The objectives of the study were to evaluate the safety and pharmacokinetic parameters of CMX001 after single and multiple doses. Single doses ranging from 0.25 to 2.0 mg/kg of body weight and multiple doses ranging from 0.1 to 1.0 mg/kg (3 total doses, administered every 6 days) were given orally. Safety was assessed using comprehensive clinical and laboratory evaluations, including enhanced monitoring for potential gastrointestinal (GI) effects using wireless capsule endoscopy (WCE). Serial plasma and pooled urine samples were collected to estimate pharmacokinetic parameters for both CMX001 and cidofovir (CDV). No adverse events occurred that prevented dose escalation. No clinically significant drug-related changes in blood chemistry, hematology, renal function, or intraocular pressure were observed. No CMX001-related gastrointestinal mucosal changes were observed by WCE. CMX001 was absorbed rapidly, with maximum plasma concentrations observed 2 to 3 h postdose. Maximum plasma drug concentration and systemic exposure of CMX001 increased approximately in proportion to dose following single and multiple doses; no significant accumulation of CMX001 or CDV was observed following multiple doses. We conclude that CMX001 is orally bioavailable and well tolerated in healthy volunteers at doses up to 2 mg/kg, approximately 140 mg in a typical adult. This is the first demonstration of the use of phospholipid conjugation technology to achieve plasma drug exposures that are expected to result in activity against multiple double-stranded DNA viruses.


Assuntos
Antivirais/farmacocinética , Citosina/análogos & derivados , Vírus de DNA/efeitos dos fármacos , Organofosfonatos/farmacocinética , Administração Oral , Adolescente , Adulto , Antivirais/sangue , Antivirais/urina , Área Sob a Curva , Disponibilidade Biológica , Endoscopia por Cápsula , Cidofovir , Citosina/sangue , Citosina/farmacocinética , Citosina/urina , Método Duplo-Cego , Esquema de Medicação , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Feminino , Humanos , Pressão Intraocular/efeitos dos fármacos , Testes de Função Renal , Masculino , Pessoa de Meia-Idade , Organofosfonatos/sangue , Organofosfonatos/urina , Placebos , Estados Unidos
6.
Antiviral Res ; 77(1): 39-49, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17904231

RESUMO

In the 21st century we are faced with the potential use of natural or recombinant VARV and MPXV as biological weapons, and the emergence of human MPXV. Such an occurrences would require therapeutic and prophylactic intervention with antivirals. Cidofovir, an antiviral approved for the treatment of cytomegalovirus retinitis in AIDS patients, has activity against poxviruses, but must be administered intravenously and is associated with nephrotoxicity. An ether-lipid analogue of CDV, CMX001 (HDP-CDV), has potent antiviral activity against a range of DNA viruses including poxviruses, excellent oral bioavailability and minimal nephrotoxicity. CMX001 and CDV are equally efficacious at protecting mice from mortality following high ectromelia virus doses (10,000 x LD(50)) introduced by the intra-nasal route or small particle aerosol. Using CMX001 at a 10mg/kg dose followed by 2.5mg/kg doses every other-day for 14 days provided solid protection against mortality and weight loss following an intra-nasal challenge of (100-200) x LD(50) of ectromelia virus. Furthermore, complete protection against mortality was achieved when administration was delayed until as late as 5 days post-infection, which is 3-4 days prior to the death of the untreated controls. This therapeutic window would be equivalent to intervening during the rash stage of ordinary smallpox.


Assuntos
Antivirais/uso terapêutico , Citosina/análogos & derivados , Vírus da Ectromelia/efeitos dos fármacos , Ectromelia Infecciosa/tratamento farmacológico , Organofosfonatos/uso terapêutico , Administração Oral , Animais , Antivirais/administração & dosagem , Cidofovir , Citosina/administração & dosagem , Citosina/metabolismo , Citosina/uso terapêutico , Ectromelia Infecciosa/prevenção & controle , Ectromelia Infecciosa/virologia , Éter , Feminino , Hepatócitos/metabolismo , Humanos , Camundongos , Camundongos Endogâmicos A , Organofosfonatos/administração & dosagem , Organofosfonatos/metabolismo
7.
Antimicrob Agents Chemother ; 51(10): 3505-9, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17646420

RESUMO

9-R-[2-(Phosphonomethoxy)propyl]-adenine (tenofovir) is an acyclic nucleoside phosphonate with antiviral activity against human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV). Tenofovir is not orally bioavailable but becomes orally active against HIV-1 infection as the disoproxil ester (tenofovir disoproxil fumarate [Viread]). We have developed an alternative strategy for promoting the oral availability of nucleoside phosphonate analogs which involves esterification with a lipid to form a lysolecithin mimic. This mimic can utilize natural lysolecithin uptake pathways in the gut, resulting in high oral availability. Since the mimic is not subject to cleavage in the plasma by nonspecific esterases, it remains intact in the circulation and facilitates uptake by target cells. Significant drops in apparent antiviral 50% effective concentrations (EC(50)s) of up to 3 logs have been observed in comparison with non-lipid-conjugated parent compounds in target cells. We have applied this technology to tenofovir with the goal of increasing oral availability, decreasing the apparent EC(50), and decreasing the potential for nephrotoxicity by reducing the exposure of the kidney to the free dianionic tenofovir. Here we report that, in vitro, the hexadecyloxypropyl ester of tenofovir, CMX157, is 267-fold more active than tenofovir against HIV-1 and 4.5-fold more active against HBV. CMX157 is orally available and has no apparent toxicity when given orally to rats for 7 days at doses of 10, 30, or 100 mg/kg/day. Consequently, CMX157 represents a second-generation tenofovir analog which may have an improved clinical profile.


Assuntos
Adenina/análogos & derivados , Fármacos Anti-HIV/uso terapêutico , Antivirais/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1 , Vírus da Hepatite B , Hepatite B/tratamento farmacológico , Organofosfonatos/síntese química , Organofosfonatos/farmacologia , Adenina/administração & dosagem , Adenina/síntese química , Adenina/química , Adenina/farmacologia , Adenina/uso terapêutico , Animais , Fármacos Anti-HIV/síntese química , Antivirais/síntese química , Linhagem Celular , Feminino , Proteína do Núcleo p24 do HIV/metabolismo , Infecções por HIV/virologia , Hepatite B/virologia , Humanos , Espectroscopia de Ressonância Magnética , Masculino , Organofosfonatos/administração & dosagem , Organofosfonatos/química , Organofosfonatos/uso terapêutico , Ratos , Ratos Sprague-Dawley , Inibidores da Transcriptase Reversa/uso terapêutico , Tenofovir
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...